Nestlé Health Science Expands Portfolio with Acquisition of VOWST from Seres Therapeutics

In a strategic move to bolster its gastrointestinal health portfolio, Nestlé Health Science has acquired the global rights to VOWST, a promising fecal microbiota product, from Seres Therapeutics. This acquisition grants Nestlé exclusive rights to develop, commercialize, and manufacture VOWST worldwide. The product is specifically designed to prevent the recurrence of Clostridioides difficile infection in adults, a significant health concern. The agreement is pending customary regulatory approvals, including the green light from Seres' shareholders, highlighting Nestlé’s commitment to advancing healthcare solutions through strategic acquisitions.

For an in-depth look at this development, you can view the full article on Medical Dialogues.